Optimal Management of Age-Related Macular Degeneration

Usha Chakravarthy, DO, PhD

Disclosures

August 30, 2022

The treatment of neovascular age-related macular degeneration (AMD) has been transformed by the use of vascular endothelial growth factor (VEGF) inhibitors.

Although these medications can offer impressive initial gains in visual acuity, those gains may be lost over time, and patients require frequent monitoring and retreatment. In many cases, eyes also progress to atrophy and fibrosis.

Prof Usha Chakravarthy, from Queens University of Belfast, Belfast, Northern Ireland, explains that some drugs may offer neuroprotection and reduce rates of atrophy.

She describes newer therapeutic options that include slow-release delivery systems to extend the interval between treatments as well as novel medications that have a more durable effect. Among the novel medications is the bispecific antibody faricimab (Vabysmo), which inhibits both VEGF and angiopoietin-2.

Prof Chakravarthy concludes with a look at the emerging option of gene therapy, in which cells are engineered to produce VEGF antagonists, which would potentially reduce the need for retreatment.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....